|
Synonyms: AMG 181 | AMG-181 | MEDI-7183 | MEDI7183
Compound class:
Antibody
Comment: Abrilumab (AMG-181, MEDI-7183) is a fully human IgG2κ monoclonal antibody which selectively targets α4β7 integrin heterodimers [1] that was developed by MedImmune. It was designed for the treatment of inflammatory bowel diseases (ulcerative colitis [2], and Crohn's disease).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Abrilumab (AMG 181) reached Phase 2 clinical evaluation. Despite evidence of beneficial effects on remission and response rates in UC patients, development was discontinued in 2016. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01164904 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis | Phase 1 Interventional | Amgen | ||
| NCT01290042 | Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181. | Phase 1 Interventional | Amgen | ||
| NCT01696396 | Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease | Phase 2 Interventional | Amgen | ||
| NCT01694485 | Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis | Phase 2 Interventional | Amgen | 2 | |
